HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

sitaxsentan

endothelin A receptor antagonist; structure in first source
Also Known As:
TBC 11251; TBC-11251; TBC11251
Networked: 46 relevant articles (4 outcomes, 15 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Barst, Robyn J: 6 articles (11/2007 - 02/2004)
2. Langleben, David: 4 articles (12/2015 - 02/2004)
3. Horn, Evelyn M: 4 articles (11/2007 - 02/2004)
4. Prous, J R: 4 articles (04/2006 - 05/2004)
5. Frost, Adaani E: 3 articles (12/2015 - 06/2005)
6. Torbicki, Adam: 3 articles (12/2015 - 03/2011)
7. Dhaun, Neeraj: 3 articles (04/2011 - 11/2007)
8. Goddard, Jane: 3 articles (04/2011 - 11/2007)
9. Webb, David J: 3 articles (04/2011 - 11/2007)
10. Shapiro, Shelley: 3 articles (11/2007 - 02/2004)

Related Diseases

1. Heart Diseases (Heart Disease)
11/01/2004 - "In its first randomised, placebo-controlled study, Sitaxsentan to Relieve Impaired Exercise-1 (STRIDE-1), sitaxsentan improved exercise capacity assessed by 6 min walk, New York Heart Association functional class, cardiac index and pulmonary vascular resistance in New York Heart Association class II, III and IV patients with idiopathic PAH, PAH related to connective tissue disease or PAH related to congenital heart disease. "
01/01/2007 - "Forty-eight patients with idiopathic PAH or PAH associated with connective-tissue disease or congenital heart disease were randomized (double-blind) to a single daily dose of either 50 mg or 100 mg sitaxsentan. "
06/01/2005 - "STRIDE I evaluated the selective endothelin A receptor antagonist, sitaxsentan (SITAX), in a 12-week randomized, double-blind, trial (178 patients) employing placebo (PBO), 100 mg or 300 mg SITAX orally once daily in PAH and included patients with NYHA class II, congenital heart disease and a BL 6MW>450 m, groups often excluded from previous trials. "
11/01/2005 - "In its first randomized, placebo-controlled study, sitaxsentan improved exercise capacity assessed by the 6-min walk test, New York Heart Association functional class, cardiac index and pulmonary vascular resistance in New York Heart Association Class II, III and IV patients with idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension related to connective tissue disease or congenital heart disease. "
02/15/2004 - "Patients with pulmonary arterial hypertension that was idiopathic, related to connective tissue disease or congenital heart disease, were randomized to receive placebo (n = 60), sitaxsentan 100 mg (n = 55), or sitaxsentan 300 mg (n = 63) orally once daily for 12 weeks. "
2. Connective Tissue Diseases (Connective Tissue Disease)
3. Anoxia (Hypoxia)
4. Ulcer
5. Pulmonary Hypertension (Ayerza Syndrome)

Related Drugs and Biologics

1. Idiopathic pulmonary hypertension
2. Endothelin A Receptor
3. Theophylline (Theon)
4. bosentan (Tracleer)
5. ambrisentan
6. Sodium
7. Endothelins (Endothelin)
8. Endothelin Receptors (Endothelin Receptor)
9. atrasentan
10. Collagen Type I (Type I Collagen)

Related Therapies and Procedures

1. Cardiopulmonary Bypass (Heart-Lung Bypass)
2. Subcutaneous Injections